An observational study in Type 1 Diabetes Mellitus and Polycystic Ovary Syndrome (PCOS), sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Observational
BACKGROUND Functional ovarian hyperandrogenism, including the polycystic ovary syndrome (PCOS), is very prevalent in women with type 1 diabetes (T1D). The pathogenic mechanisms of this association remain unclear.
HYPOTHESIS Individual factors expose or protect women with T1D to/from the development of androgen excess and PCOS. Such androgen excess in women with T1D may increase their cardiometabolic risk.
MAIN OBJECTIVE Unveiling the pathogenic mechanisms behind functional hyperandrogenism in women with T1D from a sex/gender-medicine and sexual dimorphism perspective.
MATERIAL AND METHOS We have designed a cross-sectional comparative clinical study, including 5 groups of study subjects with 12 participans per group:
i) Women with T1D \& PCOS. ii) Women with T1D without PCOS. iii) Men with T1D and normal gonadal function. iv) Women with PCOS without diabetes mellitus v) Non-hyperandrogenic control women without T1D. All groups will show similar age and body mass index. T1D groups will be matched for duration of disease.
OUTCOMES 1.1 Insulin sensitivity (hyperinsulinaemic euglycaemic clamping). 1.2 Body composition (dual-energy x-ray absorptiometry, bioelectrical impedance analysis \& sonographic studies).
1.3 Ovarian and adrenal steroidogenesis. 2.1 Differential pattern in genetic variants related with insulin signalling and response, inflammation, adiposity, gonadal function, steroidogenesis, and PCOS itself by whole exome sequencing.
2.2 Microbiopsy studies in deep subcutaneous adipose tissue and skeletal muscle tissue: 2.2.1 Differential DNA methylation patterns in genes associated with PCOS. 2.2.2 Differential transcriptomic pattern in genes associated with PCOS.
2.2.3 Differential proteomic patterns in adipose and muscle tissues. 3. Interaction between T1D and PCOS on parameters of metabolic control (intersticial blood glucose monitoring) and morbidities associated with T1D itself.
Functional ovarian hyperandrogenism, and its most frequent phenotypic expression, polycystic ovary syndrome (PCOS), has a worldwide prevalence similar to that of other pandemic metabolic entities such as type 2 diabetes, with figures ranging from 6.5% of women in our environment using strict classical criteria to 17-21% of premenopausal women from Europe and the United States, according to the most recent and inclusive diagnostic criteria. Almost all classic and non-classic cardiovascular risk factors cluster in women with this condition from their early lifespan. Conditions such as obesity, type 2 diabetes, hypertension, or dyslipidaemia, place this prevalent population at a higher risk of cardiovascular events compared to non-hyperandrogenic women. PCOS is a complex syndrome with familial aggregation, in which protective and facilitating environmental factors trigger the onset of the hyperandrogenic phenotype and its metabolic repercussions on a predisposing genotype.
POLYCYSTIC OVARY SYNDROME AND TYPE 1 DIABETES MELLITUS One of the metabolic events inherent to PCOS is a deficient organ-dependent insulin action primarily at the liver. Acting upon this central defect, obesity is the major contributor to peripheral insulin resistance in these women. Since insulin acts as a co-gonadotrophin on theca cells by stimulating various enzymes involved in ovarian and adrenal steroidogenesis, any condition associating endogenous hyperinsulinism, such as obesity or type 2 diabetes, may be associated with PCOS. However, our research group first described the association between PCOS and T1D more than 20 years ago. In that pivotal publication these adolescent and young adult women, who suffered from complete impairment of insulin secretion as the primary mechanism of disease instead of insulin resistance and compensatory hyperinsulinism, had a 3-fold increase in the prevalence of classic PCOS compared with unselected non-hyperandrogenic women from the general population.
This association has been confirmed in subsequent studies conducted by different groups worldwide. In a recent meta-analysis and systematic review by our group, we reported an increased prevalence of PCOS; in its upper range, such prevalence might reach 34% of patients with T1D, tripling the figures observed in the general population for the classic PCOS phenotype, which is the most severe in terms of cardiometabolic consequences. From a pathophysiological view, and given the obvious absence of endogenous hyperinsulinism in T1D, this relationship must be necessarily supported by exogenous subcutaneous insulin delivery. In healthy subjects, insulin directly reaches the liver through the portal circulation after its pancreatic secretion. After exerting its actions at this level, with its subsequent hepatic clearance, insulin passes into the systemic circulation at much lower concentrations than those found in the portal circulation. In PCOS and other insulin-resistant states, insulin resistance is compensated by increased pancreatic insulin secretion, resulting in portal and systemic hyperinsulinism. In contrast, in subjects with T1D, insulin is administered subcutaneously (non-physiologically) and exerts its actions on different organs and tissues, including the gonads and adrenal cortex, before reaching liver tissue at concentrations sufficient to suppress gluconeogenesis; hence, systemic insulin concentrations are necessarily supraphysiological for this reason. In contrast, hepatic insulin levels are not excessive, since this would precipitate hypoglycaemia, and this explains the constant finding of normal levels of sex hormone binding globulin (SHBG) in women with T1D and PCOS. In contrast, in women with PCOS without T1D, SHBG synthesis and secretion is decreased as a consequence of portal hyperinsulinism (certain adipokines secreted by visceral adipose tissue also contribute to this inhibition), a situation that does not occur in women with T1D in the absence of hepatic hyperinsulinism.
A few studies have reported a negative interaction between T1D and PCOS in terms of micro- or macrovascular complications. Nevertheless, the possibility that androgen excess negatively affects adipose tissue distribution in women with T1D and PCOS is plausible, placing them at risk for increased abdominal adiposity and insulin resistance. On the other hand, similarly to those women at high risk of PCOS in the general population - for example, those with obesity, even extreme obesity, or first-degree relatives of women with PCOS - who do not develop characteristics of the syndrome, not all patients with T1D, universally treated with subcutaneous insulin, will develop PCOS, indicating that a predisposition to PCOS is a conditio sine qua non for its occurrence.
DEFECTS IN OVARIAN AND ADRENAL STEROIDOGENESIS Both the fact that PCOS is not universal in women with insulin resistance and hyperinsulinism, and that insulin resistance is not universal in all women with PCOS, suggests that there is a primary defect that favours androgen excess in affected women, and that this is essential for the development of the syndrome in response to insulin or other triggers. The elegant studies conducted by the McAllister's group 20 years ago at the University of Pennsylvania demonstrated that, after several passes in primary culture, theca cells from patients with PCOS produced an excess androgen secretion compared to those of control women without the syndrome. This occurred because an intrinsically increased expression and activity of the enzyme 17α-hydroxylase/17,20-desmolase (P450c17, CYP17), the qualitative regulatory enzyme of sex steroid synthesis that catalyses both the 17α-hydroxylation of pregnenolone and progesterone, and the conversion of 17α-hydroxypregnenolone to dehydroepiandrosterone. The 17,20-desmolase activity of the enzyme is regulated by post-transcriptional mechanisms, including phosphorylation of the serine/threonine residues of the enzyme itself. The same group also demonstrated increased expression in theca cells of women with PCOS of the P450scc enzyme, which is the quantitative regulatory enzyme of ovarian and adrenal steroidogenesis that catalyses the conversion of cholesterol to pregnenolone after cholesterol transfer from the outer to the inner mitochondrial membrane by the steroidogenesis acute regulatory protein (StAR). Since any factor that could influence these theca cells in vivo were, obviously, not present after several culture passes, these alterations place excessive androgen production as a primary ovarian defect in PCOS, corroborating clinical findings such as hyper-responsiveness of 17-hydroxyprogesterone to gonadotrophin stimulation or persistent hyperandrogenemia after suppression of adrenal steroidogenesis.
In about one third of women with PCOS, hyperandrogenism also has an adrenal component. An adrenal hyper-responsiveness to corticotrophin stimulation is common in women with PCOS and hyperandrogenism of adrenal origin. A decrease in peripheral 11β-hydroxysteroid dehydrogenase-dependent cortisol regeneration can induce a compensatory hyperactivation of the corticotrophic axis, and this defect can be found at the hepatic level in PCOS, induced by ovarian hyperandrogenism itself. Another factor related to adrenal activation would be the increased expression and activity of the 17α-hydroxylase/17,20-desmolase enzyme previously mentioned. Increased phosphorylation of the serine/threonine residues of this enzyme together with that of the serine residues of the insulin receptor substrate-1 (IRS-1) could constitute a common event linking ovarian and adrenal hyperandrogenism and insulin resistance. Additionally, a partial functional defect in the action of 3β-hydroxysteroid dehydrogenase could lead to the increased Δ5/Δ4 adrenal precursor ratio observed in some women with PCOS, either caused by the hyperinsulinism characteristic of the syndrome, or by common alterations in the regulation of 17α-hydroxylase/17,20-desmolase and 3β-hydroxysteroid dehydrogenase by the MEK/ERK signalling pathway.
ADIPOSITY, VISCERAL ADIPOSITY AND BODY COMPOSITION IN PCOS The contribution of obesity to gonadal dysfunction in women and men is well-known. Excess weight increases the prevalence of classical PCOS up to 4-fold in unselected women in our setting, and 30%-50% of women with extreme obesity have features consistent with a diagnosis of PCOS. Furthermore, the estimated prevalence of obesity in women with PCOS is close to 50%, although even more remarkable is the prevalence of central adiposity, derived from a 'masculinised' distribution of adipose tissue, consisting of visceral deposition. This visceral deposition may begin in childhood and during puberty, reinforcing the hyperandrogenic phenotype in predisposed girls. During adulthood, obesity and central adiposity worsen the cardiovascular profile of women with PCOS.
Androgen excess itself influences gene expression and the proteome of visceral adipose tissue, and thus a male-like pattern of adipokine expression in visceral adipose tissue has been described. Androgens are also potent inhibitors of adipogenic differentiation, limiting the number of adipocytes and their storage capacity in subcutaneous adipose tissue, so that androgen excess may limit the adaptive capacity of adipose tissue in women with PCOS by creating a state of lipotoxicity and dysfunctional adipocytokine secretion. Oxidative stress and subclinical chronic inflammation inherent to PCOS also play a role in the inability to physiological expansion of adipose tissue and its metabolic dysregulation. Ultimately, the interrelationship between PCOS and abdominal obesity is the result of a vicious circle in which androgenic excess favours the deposition of abdominal visceral fat, which directly facilitates androgenic excess of ovarian and adrenal origin through the secretion and effect of autocrine, paracrine and endocrine mediators [down-regulation of adiponectin and up-regulation of tumour necrosis factor-alpha (TNF-α), IL-6 and leptin], or indirectly through the induction of insulin resistance and compensatory hyperinsulinism.
INSULIN RESISTANCE, INFLAMMATION AND OXIDATIVE STRESS IN PCOS PATHOPHYSIOLOGY Euglycaemic clamp studies are consistent with a post-ligand binding defect in the insulin receptor affecting the intracellular metabolic signalling pathway in adipose tissue; an alteration supported by findings from metabolomic studies showing an increase in plasma long-chain fatty acids and glycerol, suggesting increased lipolysis, likely related to decreased sensitivity to insulin action in adipose tissue. Consistent with this, a substantial number of women with PCOS have increased phosphorylation of serine residues of the insulin receptor, whose function is inhibited by reducing the intrinsic kinase activity of its tyrosine residues. Such phosphorylation is mediated by TNF-α, especially in those patients with abdominal obesity, a scenario derived from the hyperandrogenic stimulus to the release of this cytokine by mononuclear cells, both after fasting and in response to glucose intake. In other women, phosphorylation of IRS-1 or activation of phosphatidylinositol-3-kinase aggravates insulin resistance. However, insulin resistance at the adipocyte level may also be mediated by another complementary mechanism, namely, the infiltration of this tissue by macrophages. Inflammatory macrophages characterised by CD11c expression cluster around adipocytes forming crown-like structures, the density of which directly correlates with the degree of insulin resistance. These macrophages will secrete cytokines such as TNF-α, promoting a local inflammatory environment. Women with PCOS show increased CD11c expression in macrophages and crown-like structures in subcutaneous adipose tissue in direct proportion to circulating testosterone levels. In muscle tissue of women with PCOS, the mitogenic pathway of the insulin receptor, MAPK-ERK 1/2, is also constitutively activated enhancing increased phosphorylation of IRS-1 serine residues. The presence of mitochondrial dysfunction in women with functional hyperandrogenism may contribute to the presence of insulin resistance. Oxidative stress induced by this mitochondrial dysfunction is involved in the pathogenesis of PCOS and metabolic complications related to hyperandrogenism. Although some studies have failed to confirm a primary impairment of mitochondrial function in PCOS, biomarkers of oxidative stress are increased in these women regardless of the presence of weight excess. Moreover, the alterations in mitochondrial function of hyperandrogenic women with insulin resistance resemble those of patients with type 2 diabetes.
GENETIC PREDISPOSITION PCOS is a complex multigenic condition that arises from the interaction between protective and predisposing genetic variants, which may have been selected over the ages by evolution due to an ancestral survival advantage, with environmental factors playing a determining role in the expression of the hyperandrogenic phenotype. Among others, genomic variants in genes regulating androgen biosynthesis, insulin action and inflammation may be associated with predisposition to PCOS. A meta-analysis of large-scale genome-wide association studies, including more than 10,000 women with PCOS and 100,000 controls, all of European origin, identified 14 loci associated with hyperandrogenism, gonadotrophin regulation and testosterone concentrations in affected women, and correlations with obesity, insulinemia, type 2 diabetes, lipid levels and coronary atherosclerotic disease, indicating a shared genetic architecture between these metabolic alterations and PCOS.
These pathophysiological mechanisms described in women with PCOS from the general population have not been studied in women with T1D. Therefore, the description of facilitating and protective factors associated with the development or absence of functional hyperandrogenism and PCOS in women with T1D is the main objective of the present research project.
HYPOTHESIS There are individual factors that expose or protect women with T1D to/from the development of androgen excess and PCOS, despite the iatrogenic systemic hyperinsulinism they all experience as a result of the subcutaneous administration of insulin they require for survival. Androgen excess in women with T1D may increase their cardiometabolic risk.
STUDY OBJECTIVES MAIN OBJECTIVE: Unveiling the pathogenic mechanisms behind functional hyperandrogenism in women with T1D from a sex medicine perspective.
Primary aims: To identify predisposing/protective factors associated with the development of functional hyperandrogenism in women with T1D by phenotyping these women using state-of-the-art techniques for the assessment of:
1.1. Insulin sensitivity. 1.2. Body composition. 1.3. Ovarian and adrenal steroidogenesis.
Secondary aims: Identification of relevant molecular-genetic factors associated with the development of functional hyperandrogenism in women with T1D 2.1. Identify genomic variants in genes/proteins related to insulin signalling and action, adiposity, inflammation, steroidogenesis, and PCOS itself (Genomics).
2.2. Description of differential DNA methylation patterns in deep subcutaneous adipose and skeletal muscle tissues (Epigenomics).
2.3. Description of differential gene expression profiles in adipose and muscle tissues (Transcriptomics).
2.2. Description of differential proteomic profiles in adipose and muscle tissue (Proteomics).
3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's planned enrollment of 60 is below the median of 125 across 792 observational studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal is the lead sponsor of 83 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Premenopausal adult women with type 1 diabetes mellitus presenting with or without polycystic ovary syndrome.
Non--hyperandrogenic women with type 1 diabetes INCLUSION CRITERIA
Women with type 1 diabetes and polycystic ovary syndrome INCLUSION CRITERIA
EXCLUSION CRITERIA
Men with T1D and normal gonadal function of similar age, , and duration of diabetes.
INCLUSION CRITERIA
EXCLUSION CRITERIA
Women with PCOS of similar age and BMI. INCLUSION CRITERIA
EXCLUSION CRITERIA
Non-hyperandrogenic control women with regular menses of similar age and BMI. INCLUSION CRITERIA
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INCLUSION CRITERIA * Premenopausal women between 18 and 45 years old. * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency. * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion). * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry. * Menarche at least three years prior to study entry. EXCLUSION CRITERIA * Honeymoon period of T1D. * Pregnancy or lactation. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.
Other: Type 1 diabetes mellitus · Other: Sex dimorphism
INCLUSION CRITERIA * Women between 18 and 45 years old. * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency. * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion). * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry. * Menarche at least three years prior to study entry. * PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS. EXCLUSION CRITERIA * Honeymoon period of T1D. * Pregnancy/lactation. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. reatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.
Other: Type 1 diabetes mellitus · Other: Elevated circulating androgen levels · Other: Sex dimorphism
INCLUSION CRITERIA * Age between 18 and 45 years old. * Diagnosis of type 1a diabetes at least 12 months before inclusion in the study, confirmed by positive autoimmunity and complete insulin deficiency. * Treatment with subcutaneous insulin therapy (multiple doses or continuous infusion). * Availability of metabolic control data (continuous interstitial blood glucose monitoring) at least in the month prior to study entry. EXCLUSION CRITERIA * Honeymoon period of T1D. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia. * Diagnosis of male hypogonadism.
Other: Type 1 diabetes mellitus · Other: Elevated circulating androgen levels · Other: Sex dimorphism
INCLUSION CRITERIA * Women between 18 and 45 years old. * Menarche at least three years prior to study entry. * PCOS diagnosis based on the 2012 American NIH consensus criteria, including the Rotterdam and AE-PCOS. EXCLUSION CRITERIA * Pregnancy/lactation. * Previously known carbohydrate metabolism abnormalities (prediabetes or type 2 diabetes). * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.
Other: Elevated circulating androgen levels · Other: Sex dimorphism
INCLUSION CRITERIA * Women between 18 and 45 years old. * Menarche at least three years prior to study entry. * Presence of regular menses. * Lack of signs or symptoms of functional hyperandrogenism. EXCLUSION CRITERIA * Pregnancy/lactation. * Previously known carbohydrate metabolism disturbances. * Thyroid hormone dysfunction or hyperprolactinaemia. * Diagnosis of non-classical congenital adrenal hyperplasia or other secondary causes of hyperandrogenism. * Diagnosis of other serious chronic disease. * Treatment with oral contraceptives or glucocorticoid therapy in the 3 months prior to inclusion in the study.
Other: Sex dimorphism
A diagnosis of type 1a diabetes mellitus
Androgen excess exposition due to a diagnosis of polycystic syndrome or male sex
Effects of sex on outcomes measures
Differences in insulin sensitivity between study subgroups
Study of sensitivity to insulin action by hyperinsulinaemic euglycaemic clamp. Clamping will be conducted in the follicular phase fo women's study participants. In this protocol free fatty acids will be also determined in stored samples.
Time frame: At baseline
Fat mass percentage
Body composition studies: Fat mass percentage with respect to total body weight. Methodology: Bioelectrical impedance analysis by Monitor VitalScan Medeia® System device (United States, CA).
Time frame: At baseline
Phase angle 50 KHz
Methodology: Bioelectrical impedance analysis by Monitor VitalScan Medeia® System device (United States, CA).
Time frame: At baseline
Peritoneum-vertebral column fat thickness
Ultrasound assessment of fat compartments, determined using Toshiba Nemio ZG SSA-580ª ultrasound equipment (Toshiba Medical Systems, S.A., Alcobendas, Madrid) following the protocol previously validated and reported by our research group (PMID: 23386652).
Time frame: At baseline
Trunk fat mass %
Dual energy X-ray absorptiometry (DEXA). Hologic QDR Explorer® equipment.
Time frame: At baseline
Differences in ovarian and adrenal steroidogenesis between study subgroups
The circulating sex steroid profile will be assessed at baseline and at 60 minutes after stimulation of adrenal steroidogenesis with administration of 250 mcg i.v. of 1-24 ACTH. This profile will be determined in serum samples by liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) at the Laboratory of Clinical Biology, Ghent University, Belgium, using a triple-quadrupole mass spectrometer (AB Sciex, Toronto, Canada). The 24h urine steroid metabolomic profile will be analysed by gas chromatography-mass spectrometry (GC-MS). The analytical procedure will be performed by pre-extraction of urine (solid phase extraction with Sep-Pak C18 columns), followed by hydrolysis, solid phase re-extraction and double derivatization of the steroids to their methoxymethyltrimethylsilyl derivatives. The extracts obtained will be injected into the Shimadzu GCMS QP2010 instrument.
Time frame: At baseline
Identify genomic variants in genes/proteins related to insulin signalling and action, adiposity, inflammation, steroidogenesis, and PCOS itself
This approach will permit a detailed characterization of all the genetic variants present in the coding portion of the human genome, covering not only genes already identified to be associated with PCOS, but also other genes related to the pathophysiology of PCOS in women with T1D. Bioinformatic analysis of WES will be focused on genes that have been linked to PCOS and functional hyperandrogenism in populations of European ancestry in previous candidate gene studies and genome wide association studies, leaving open the possibility of analyzing other genes of interest depending on the results obtained in other studies of the project and the data published by other groups. Genomic DNA will be isolated from peripheral bood with the FlexiGene DNA Qiagen kit and submitted to an external biotech company (Macrogen Spain) for conducting these studies. Genomic DNA will be isolated from peripheral blood with the FlexiGene DNA Qiagen kit and submitted to an external biotech company.
Time frame: At baseline
Description of differential DNA methylation patterns in deep subcutaneous adipose and skeletal muscle tissues (Epigenomics)
Oxford Nanopore sequencing enables direct detection of methylated cytosines from isolated genomic DNA without the need for bisulphite conversion. The Adaptive Sampling RRMS panel (Reduced Representation Methylation Sequencing) protocol enables to target the regions of human genome highly enriched for CpG sites, including a total number of 7-8M CpGs, and multiplexing up to 4 samples on a single PromethION flow cell.
Time frame: At baseline
Description of differential gene expression profiles in adipose and muscle tissues (Transcriptomics)
RNA from adipose and muscle will be isolated using the Fatty Tissue and Total RNA Purification kits (Norgen Biotek). RNA quantity and quality shall be evaluated with the Qubit fluorimeter and Agilent Bioanalyzer. RNAseq libraries will be prepared following the protocol included in the Illumina® Stranded Total RNA Prep, Ligation with Ribo-Zero Plus kit. Sequencing will be performed using an Illumina NovaSeqXPlus (1x100bp) with \>40M reads/sample. Targeted expression of selected genes (chosen according RNAseq results) will be assessed by real-time qPCR in a LightCycler480 with products from AnyGenes company.
Time frame: At baseline
Description of differential proteomic profiles in adipose and muscle tissue (Proteomics)
Comparative proteome analysis with isobaric tandem mass tag (TMT). Samples will be processed according to the protocol described in Carmona L. et al. (PMID: 37171157) on S-Trap columns. The resulting peptides will be labelled with TMT18plex labels according to the manufacturer's instructions (Thermo Scientific). The labelled peptides shall be separated on an Ultimate 3000 nanochromatograph on a C18 reverse phase column.
Time frame: At baseline
Insulin requirements/day adjusted for weight
To evaluate the interaction between T1D and PCOS on parameters of metabolic control and morbidities associated with T1D itself.
Time frame: At baseline
Time in range
Interstitial blood glucose monitoring: time in range \[between 70 and 180 mg/dl (%)\]
Time frame: Since 4 weeks prior to inclusion in study
Ambulatory blood pressure
Blood pressure determined according to 24-hour ambulatory blood pressure monitoring
Time frame: At baseline
Subclinical atherosclerosis: Differences in carotid intimomedial thickness between study subgroups
Imaging will be conducted using a high-resolution 7-15 MHz phased-array transducer (EPIQ 5, Philips Healthcare, Bothell, WA, USA) by the same trained operator in all study participants. This operator will be blinded to the women's features and their group allocation. Under controlled light and temperature conditions, studies will be performed by positioning the women in a supine position with a 35-degree incline of the head and torso, and a 45 degrees right-turn or left-turn, respectively, of the head. The left and right common carotid arteries will be explored in B-mode in longitudinal and transversal planes, to rule out the presence of plaque that might interfere with cIMT measurements. The posterior carotid wall at 1 cm of the common carotid bulb will be imaged and cIMT estimated by visual assessment (average of five manual measurements) of the distance between the lumen/intima and intima/adventitia interphases in longitudinal frames acquired during arterial diastole.
Time frame: At baseline
Plan to share: Undecided — All data sets generated and/or analyzed during the current study will not be publicly available but will be available from the Principal Investigator on reasonable request.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal